Cancer treatments can induce a form of senescence that halts cellular division while allowing continued secretion of tumor-promoting proteins. We recently found that antiangiogenic treatment resistance can lead to a transient hijacking of the senescence-controlled secretory machinery that, when therapeutically targeted during treatment cessation, can blunt rebound tumor growth.
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Antiangiogenic therapy aims to disrupt blood vessel formation that is critical for the growth and dissemination of tumor cells. The vascular endothelial growth factor (VEGF) has been the primary target for several clinically approved drugs in the metastatic setting; however, initial efficacy is undermined by resistance for the majority of patients. 4 In a paper recently published in Cell Reports, we undertook a series of studies to investigate the role of senescence in promoting tumor growth after antiangiogenic therapy. 5 This was done for three reasons. First, angiogenesis inhibitors have been reported to promote metastasis in certain preclinical settings. 6 While the clinical implications of such findings remain unclear, it is possible that these effects may be most consequential after therapy has stopped -something that occurs in patients after treatment failure or toxicity. 7 Second, VEGF pathway disruption has also been shown to induce senescence phenotypes in both clinical and preclinical studies, 8 but the durability of these cellular changes remain understudied. Third, VEGF pathway inhibition can induce a broad array of SASP-like circulating cytokine changes in patients. These systemic blood-protein changes have been investigated as surrogate biomarkers of response, but may also be contributors to post-treatment disease progression in patients who have relapsed. 9 In our studies, we evaluated senescence markers and tumor growth after resistance to clinically approved VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs), and again after treatment had been stopped for short-term (24-48 hrs) or long-term (2-6 months) periods. 5 We found that VEGFR TKI-resistant mouse and human tumor cells originating from kidney carcinoma, breast carcinoma, or melanoma, progressed much more rapidly than controls when implanted orthotopically into mice when treatment was halted (representing short-term withdrawal conditions). Interestingly, these withdrawal-mediated tumor growth rebounds were found to diminish following long-term periods of drug removal, suggesting that tumor-promoting phenotypes were reversible for most cells. We next examined nine tumor and non-tumor cell lines resistant to two VEGFR TKIs (sunitinib or axitinib) and found all were positive for senescence markers that included increased cell size, p21 upregulation, and SA-β-gal. However, these markers were inconsistent amongst the cell lines and all ultimately diminished following protracted periods of drug removal. In subsequent experiments, we utilized
John.Ebos@RoswellPark.org Roswell Park Comprehensive Cancer Center, Center for Genetics and Pharmacology, Elm and Carlton Streets, Buffalo, NY 14263-0001 FDG), a fluorogenic substrate for β-gal activity to identify live senescent marker-positive cells. 10 Using flow cytometric sorting, we found that C 12 FDG + (high SA-β-gal expressing) cell populations had increased growth rates in vitro and in vivo compared to C 12 FDG − (low SA-β-gal expressing) cells. Finally, using transcriptomic and protein analysis, we observed that VEGFR TKIresistant cells had an SASP-mimicking antiangiogenic therapy induced secretome (ATIS) that could persist during short-term treatment withdrawal periods. We found the ATIS was maintained after short treatment gaps and coincided with tumor growth accelerations following implantation into mice. Critically, our results showed that therapeutic targeting of mammalian target of rapamycin (mTOR) and interleukin 6 (IL-6) -both regulators of the SASP -could limit withdrawal-mediated tumor growth (Figure 1 ).
Taken together, these studies suggest that there is a short 'window' immediately after withdrawal of treatment after VEGFR TKI resistance where tumor growth is promoted by sub-populations of cells enriched for senescence marker positivity. These transient pseudosenescent cells have reversible secretory profiles closely associated with cellular aging. It is possible that senescencetargeted treatment strategies -particularly those targeting SASP regulation such as mTOR or IL-6 -may be effective in patients who have failed antiangiogenic therapy. 
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